AbbVie Inc. ABBV reported second-quarter 2025 adjusted EPS of $2.97, which beat the Zacks Consensus Estimate of $2.89. The ...

AbbVie submitted a supplemental new drug application for Venclexta plus Calquence treatment in previously untreated chronic ...

Venclexta has been on the market since 2016 for CLL, initially for 17p-mutated cases, and since 2019 has been used as a first ...

VENCLEXTA (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their ...

AbbVie seeks FDA approval for a groundbreaking oral treatment combining venetoclax and acalabrutinib, promising a new era in ...

AbbVie is seeking a new way to fight chronic lymphocytic leukemia by combining its oncology drug Venclexta with another ...

AbbVie ABBV is set to report second-quarter 2025 earnings on July 31, before the opening bell. The Zacks Consensus Estimate ...

Roche is in discussions with HHS to launch a direct-to-patient drug distribution model. CEO Thomas Schinecker said the move is being considered as a way to reduce prices for patients, pointing to ...

Here are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.

Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study. In the high-dose cohort from the ongoing Phase Ib/IIa Brainshuttle AD ...

Roche touted rapid amyloid clearance from the brains of patients with Alzheimer’s disease after treatment with its anti-amyloid antibody trontinemab on Sunday. In a highly anticipated presentation at ...

Joseph Michael Roche died peacefully on July 11, 2025, in Naperville, Illinois, surrounded by family. He was 81 years old. Joe was born on March 23, 1944, in Philadelphia, Pennsylvania, to the late… ...